N/A N=357 Hemangioma Associated With High Rates of Morbidity
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=261 Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas
Hemangioma
Primary: Frequency of Hepatic Hemangiomas Identified on Abdominal Ultrasound — 24 participants
Phase 4 N=34 The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma
Hemangioma
Primary: Number of Participants With Clinical Response From Baseline in Hemangioma Volume Measured by MRI or SONO — 14; 16 Participants
Phase 2 N=10 Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Hereditary Hemorrhagic Telangiectasia
Primary: Change in Lesion Area of Treated Telangiectasia. — -6; -8 mm^2
N/A N=27 Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
Port Wine Stain
Primary: Change From Baseline in a* and E at 8 Weeks — 1.27; 0.43; 4.08; 2.59 units on a scale
Phase 3 N=460 Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy
Infantile Hemangioma
Primary: Interim Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at Week 24 Compared to Baseline Based on the Intra-patient Blinded Centralized…
N/A N=22 Clinical Evaluation of the Treatment of Spider Angioma
Spider Angioma
Primary: Physician's Global Assessment Scale for Improvement of Spider Angioma — 4.5 score on a scale
Phase 2 N=141 Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)
Infantile Hemangioma
Primary: Number of Participants With Partial Response of Hemangioma Volume as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm and Compared With Untreated Controls…
Phase 3 N=377 Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
Hemangioma
Primary: The Primary Outcome Measure Was Any Response at 6 Months — 178; 173 Participants — p=<0.05
Phase 3 N=28 A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation
Hypervascular Tumor and Arteriovenous Malformation
Primary: Success Rate of Embolization in the Target Vessel — 100; 96.4 Percentage of participants
Phase 1 N=7 Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Choroidal Neovascularization
Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…
Phase 2 N=53 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Uveal Melanoma · Liver Metastases
Primary: Response of Liver Metastases — 0; 0; 5; 3 participants
Phase 2 N=55 Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
Obscure Gastrointestinal Bleeding · Angiodysplasia · Gastric Antral Vascular Ectasia
Primary: Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months — 20; 1 participants — p=0.00000013
Phase 2 N=18 Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Epistaxis · Hereditary Hemorrhagic Telangiectasia
Primary: Severityof Epistaxis — -0.4578; -1.4375 units on a scale
Phase 2 N=10 Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT)
Primary: Epistaxis Using the Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Feritin Levels..
Phase 2 N=20 Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT)
Primary: Measurement of Epistaxis in Patients With HHT as Measured by the HHT Foundation Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Ferritin Levels.